{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:18:48Z","timestamp":1773710328987,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bulcan.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:26:03Z","timestamp":1725276363000},"page":"909-910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elranatamab en monoth\u00e9rapie dans le my\u00e9lome multiple apr\u00e8s au moins trois lignes th\u00e9rapeutiques ant\u00e9rieures"],"prefix":"10.1016","volume":"111","author":[{"given":"Erwann","family":"Collomb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2932-2957","authenticated-orcid":false,"given":"Carolyne","family":"Croizier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bulcan.2024.06.006_bib0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bulcan.2021.10.007","article-title":"[New European approval: idecabtagene vicleucel in relapsed and\/or refractory myeloma after at least 3\u00a0lines of treatment]","volume":"109","author":"Croizier","year":"2022","journal-title":"Bull Cancer (Paris)"},{"issue":"9","key":"10.1016\/j.bulcan.2024.06.006_bib0035","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bulcan.2023.01.021","article-title":"[Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy]","volume":"110","author":"Le Grand","year":"2023","journal-title":"Bull Cancer (Paris)"},{"issue":"9","key":"10.1016\/j.bulcan.2024.06.006_bib0040","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2024.06.006_bib0045","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2022-162738","article-title":"Elranatamab in combination with daratumumab for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort","volume":"140","author":"Grosicki","year":"2022","journal-title":"Blood"},{"issue":"16_suppl.","key":"10.1016\/j.bulcan.2024.06.006_bib0025","doi-asserted-by":"crossref","first-page":"TPS8065","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8065","article-title":"MagnetisMM-6: an open-label, multicenter, randomized phase 3 study of elranatamab\u00a0+\u00a0daratumumab\u00a0+\u00a0lenalidomide (EDR) versus daratumumab\u00a0+\u00a0lenalidomide\u00a0+\u00a0dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)","volume":"41","author":"Grosicki","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124002650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124002650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T21:05:29Z","timestamp":1727125529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124002650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0007455124002650"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.06.006","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elranatamab en monoth\u00e9rapie dans le my\u00e9lome multiple apr\u00e8s au moins trois lignes th\u00e9rapeutiques ant\u00e9rieures","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}